Last edition
News about "Hospital-Acquired Pneumonia"
Omnix Medical has initiated patient dosing in its Phase 2 clinical trial of OMN6, a novel antimicrobial peptide designed to treat severe multidrug-resistant Acinetobacter baumannii infections, a critical global health threat with limited treatment options.
Hospital-Acquired Pneumonia | 05/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members